Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598088 · ClinicalTrials.gov registry record · NA
Safety and Acceptability Study of a Non-Hormonal Ring
A NA study, sponsored by Daré Bioscience.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT03598088: Completed NA study, sponsored by Daré Bioscience.
NCT03598088 is a NA study that has completed, run by Daré Bioscience. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03598088, a NA study, has completed, sponsored by Daré Bioscience.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a feasibility, multi-center, open-label, non-significant risk device study for a non-hormonal contraceptive ring.
Primary Outcome
All participants had fewer than 5 progressively motile sperm per high power field (PMS/HPF) in all cycles during Ovaprene use.
Interventions
- DEVICE Ovaprene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-05-23 |
| Est. Completion | 2019-11-15 |
| Phase | NA |
What the finished NCT03598088 record still lists
NCT03598088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Ovaprene is the first listed.
NCT03598088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03598088 about?
NCT03598088 is a clinical study titled "Safety and Acceptability Study of a Non-Hormonal Ring". This is a feasibility, multi-center, open-label, non-significant risk device study for a non-hormonal contraceptive ring.
What is the current status of trial NCT03598088?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2018-05-23. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT03598088?
The interventions under investigation include: Ovaprene (DEVICE).
Who is sponsoring clinical trial NCT03598088?
This trial is sponsored by Daré Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03598088's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI